Latest news
Context drops bispecific T-cell engager on cost-cutting initiative - Clinical Trials ArenaClinical Trials Arena · Fri, 07 Aug 2026 10:14:16 GMTContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 09:55:15 GMTSara Coca Membribes: MDX2001 is a First-in-Human Multispectic T-Cell Engager in Solid Tumors - OncodailyOncodaily · Wed, 05 Aug 2026 19:07:53 GMTWhat Oblenio’s Phase I trial means for autoimmune drug discovery - Drug Target ReviewDrug Target Review · Wed, 05 Aug 2026 14:00:01 GMTOblenio Doses First Patients in Phase 1a Trial of Trispecific T-Cell Engager LBL-051 - BioPharm InternationalBioPharm International · Tue, 04 Aug 2026 17:05:26 GMTMarengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion - PR NewswirePR Newswire · Tue, 04 Aug 2026 11:00:00 GMTVaxcellbio launches global co-development program for NRC-based NK cell therapy for multiple myeloma - koreabiomed.comkoreabiomed.com · Tue, 04 Aug 2026 06:22:28 GMTCNTX: Promising T cell engager pipeline targets high unmet needs in solid tumors with strong early data - TradingViewTradingView · Sat, 01 Aug 2026 20:47:00 GMT